Quality of life in patients with juvenile arthritis: adalimumab might make a difference by Denisova, Rina et al.
POSTER PRESENTATION Open Access
Quality of life in patients with juvenile arthritis:
adalimumab might make a difference
Rina Denisova, Ekaterina Alexeeva, Saniya Valieva, Tatyana Bzarova, Elena Mitenko
*, Tatyana Sleptsova,
Kseniya Isayeva
From 18th Pediatric Rheumatology European Society (PReS) Congress
Bruges, Belgium. 14-18 September 2011
Introduction
Juvenile arthritis (JA) leads to premature impairment of
pediatric physical health, psychological and social limita-
tions, that considerably worsen health related quality-of-
life of patients. That is why improvement of health
related quality-of-life is one of the main aims of treat-
ment of patients with juvenile arthritis.
Purpose
Evaluate influence of adalimumab therapy on HRQOL
of children with different forms of juvenile arthritis.
Material and methods
There were examined 66 children (median age 10 (3; 16)
years). From them there were 44 girls, 23 boys, 23 per-
sons with oligoarticular juvenile idiopathic arthritis
(JIA), 30-with polyarticular JIA, 3-with systemic JIA and
10 – with Juvenile Enthesitis related arthritis. 58 (88%)
children were treated with adalimumab for more than a
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HRQOL was performed by the help of questionnaires
PedsQL Generic Core Scale (PedsQL GCS), PedsQL
Rheumatology Module (PedsQL RM).
Results
HRQOL of children with JA before the conducted ther-
apy in all scales of questionnaire PedsQL GCS was con-
siderably lower in comparison with population norm
(p<0,001). To week 54 of infliximab therapy there was
detected statistically reliable increase of HRQOL values
in all scales of the questionnaires (p<0,001). By self
report of the questionnaires PedsQL RM by the scale
“pain and hurt” HRQOL Me increased from 37 to 100,
by the scale “daily activities”–from 75 to 100, by the
scale “treatment”–from 45 to 74, by the scale “worry”
from 45 to 65, by the scale “communication” from 55 to
75. By proxy report from 25 to 100, from 55 to 100,
from 30 to 60, from 35 to 62, from 50 to 70, respec-
tively. By self report of the questionnaire PedsQL GCS
total score of HRQOL increased from 47 to 79,23, by
the scale of physical health – from 43 to 86,15, by the
scale of emotional functioning – from 45 to 72,16 and
by the scale of social functioning – from 50 to 79,38. By
proxy report from 38 to 75,14, from 37 to 81, from 35
to 68,28, from 40 to 72,69, respectively. To the year of
receiving the therapy by self report health related qual-
ity-of-life differed from population norm only by the
scale of social functioning (p<0,01), and by proxy report
HRQOL was lower only by the scales of emotional and
social functioning (p<0,001).
Conclusion
Adalimumab administration in pediatric rheumatologic
practice increases physical, psychological, social adapta-
tion of patients, allows changing diagnosis of such a
severe disabling disease, as JA, stopping steadily progres-
sing disease course and preventing severe disability in
such tender age.
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